Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042

NCT07222878 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Epilepsy
Alzheimer Disease
Epilepsy Intractable

Interventions

DRUG: NPT 2042 (Reference formula/Formulation 1)
DRUG: NPT 2042 (Test formula/Formulation 2)
DRUG: NPT 2042 (Test formula/Formulation 2)

Sponsor

NeuroPro Therapeutics, Inc.